Characteristics | Hazard ratio | 95%CI | P |
---|---|---|---|
Age (years, <46 vs. ≥ 46) | 1.558 | 1.044–2.326 | 0.030 |
Sex (male vs. female) | 0.447 | 0.264–0.754 | 0.003 |
T-stage (T1~2 vs. T3~4) | 1.386 | 0.914–2.101 | 0.124 |
N-stage (N0 vs. N1~3) | 0.978 | 0.628–1.524 | 0.923 |
Clinical stage (I/II vs. III/IV) | 1.817 | 1.091–3.025 | 0.022 |
Recurrence (no vs. yes) | 1.560 | 1.018–2.391 | 0.041 |
Metastasis (no vs. yes) | 2.023 | 1.177–3.478 | 0.011 |
VEGF (low expression vs. over-expression) | 2.112 | 1.277–3.495 | 0.004 |
Survivin (low expression vs. over-expression) | 2.132 | 1.301–3.494 | 0.003 |